558 results on '"Fries, Dietmar"'
Search Results
202. Loss or Dilution—A New Diagnostic Method to Assess the Impact of Dilution on Standard Laboratory Parameters.
- Author
-
Innerhofer, Nicole, Rajsic, Sasa, Ronzani, Marco, Breitkopf, Robert, Gollmann Tepeköylü, Can, Velik-Salchner, Corinna, Schlosser, Lisa, Fries, Dietmar, Streif, Werner, Schirmer, Michael, and Martini, Judith
- Subjects
- *
CARDIOPULMONARY bypass , *BLOOD volume , *DILUTION , *CARDIAC surgery , *FLUID therapy , *HEMODILUTION - Abstract
Intraoperative fluid therapy is regularly used in patients undergoing cardiac surgery procedures with cardiopulmonary bypass (CPB). Although fluid administration has several advantages, it unavoidably leads to hemodilution. The hemodilution may further influence the interpretation of concentration-based laboratory parameters like hemoglobin (Hgb), platelet count (PLT) or prothrombin time (PT). These all parameters are commonly used to guide blood product substitution. To assess the impact of dilution on these values, we performed a prospective observational study in 174 patients undergoing elective cardiac surgery. We calculated the total blood volume according to Nadler's formula, and fluid therapy was correlated with a newly developed dilution coefficient formula at the end of CPB. Intravenously applied fluids were measured from the beginning of the anesthesia (baseline, T0) and 15 min after the end of protamine infusion (end of CPB, T1). The amount of the administered volume (crystalloids or colloids) was calculated according to the percentage of the intravascular fluid effect, and intraoperative diuresis was further subtracted. The median blood volume increased by 148% in all patients at T1 compared to the calculated total blood volume at T0. This led to a dilution-dependent decrease of 38% in all three parameters (Hgb 24%, corrCoeff = 0.53; PLT 41%, corrCoeff = 0.68; PT 44%, corrCoeff = 0.54). The dilution-correlated decrease was significant for all parameters (p < 0.001), and the effect was independent from the duration of CPB. We conclude that the presented calculation-based approach could provide important information regarding actual laboratory parameters and may help in the guidance of the blood product substitution and potential transfusion thresholds. Further research on the impact of dilution and related decision-making for blood product substitution, including its impact on morbidity and mortality, is warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
203. 7th Innsbruck Winter Symposium for Coagulation, Congress Center Innsbruck, November 5th to 6th, 2010.
- Author
-
Fries, Dietmar, Innerhofer, Petra, Haas, Thorsten, Martini, Wenjun Zhou, Zander, Rolf, Johansson, Pär I., Schöchl, Herbert, Voelckel, Wolfgang, Solomon, Cristina, Kozek-Langenecker, Sibylle, Dubick, Michael A., Kheirabadi, Bijan S., Fenger-Eriksen, Christian, Grottke, Oliver, and Rossaint, Rolf
- Abstract
The article highlights several papers discussed at the 7th Innsbruck Winter Symposium for Coagulation held at the Congress Center Innsbruck in Austria from November 5 to 6, 2010. The main focus of the event was Haemostatis in Massive Bleeding and Trauma and it was supported by AOP Orphan Pharmaceuticals AG, CSL Behring, among others. Wenjun Zhou Martini talked about the association of trauma with coagulation disorders. A discussion was made about the detection and impact of hyperfibrinolysis in trauma.
- Published
- 2010
- Full Text
- View/download PDF
204. The importance of religious affiliation and culture on end-of-life decisions in European intensive care units.
- Author
-
Sprung, Charles, Maia, Paulo, Bulow, Hans-Henrik, Ricou, Bara, Armaganidis, Apostolos, Baras, Mario, Wennberg, Elisabet, Reinhart, Konrad, Cohen, Simon, Fries, Dietmar, Nakos, George, and Thijs, Lambertius
- Subjects
INTENSIVE care units - Abstract
A correction to the article "The importance of religious affiliation and culture on end-of-life decisions in European intensive care units," that was published in the previous issue is presented.
- Published
- 2007
- Full Text
- View/download PDF
205. Low-Molecular-Weight Heparin Resistance and Its Viscoelastic Assessment in Critically Ill COVID-19 Patients.
- Author
-
Bösch, Johannes, Rugg, Christopher, Schäfer, Volker, Lichtenberger, Philipp, Staier, Nikolai, Treichl, Benjamin, Rajsic, Sasa, Peer, Andreas, Schobersberger, Wolfgang, Fries, Dietmar, and Bachler, Mirjam
- Subjects
- *
LOW-molecular-weight heparin , *COVID-19 , *CRITICALLY ill , *DRUG monitoring , *INTENSIVE care units - Abstract
Critically ill COVID-19 patients present an inflammatory and procoagulant status with a high rate of relevant macro- and microvascular thrombosis. Furthermore, high rates of heparin resistance have been described; yet, individualized anticoagulation by drug monitoring has not been sufficiently researched. We analyzed data from critically ill COVID-19 patients treated at Innsbruck Medical University Hospital with routinely adapted low-molecular-weight heparin (LMWH) doses according to anti-Xa peak levels, and regularly performed ClotPro analyses (a viscoelastic hemostatic whole blood test). A total of 509 anti-Xa peak measurements in 91 patients were categorized as below (<0.008 IU/mL/mg), within (0.008–0–012 IU/mL/mg) or above (> 0.012 IU/mL/mg) expected ranges with respect to the administered LMWH doses. Besides intergroup comparisons, correlations between anti-Xa levels and ClotPro clotting times (CTs) were performed (226 time points in 84 patients). Anti-Xa peak levels remained below the expected range in the majority of performed measurements (63.7%). Corresponding patients presented with higher C-reactive protein and D-dimer but lower antithrombin levels when compared with patients achieving or exceeding the expected range. Consequently, higher enoxaparin doses were applied in the sub-expected anti-Xa range group. Importantly, 47 (51.6%) patients switched between groups during their intensive care unit (ICU) stay. Anti-Xa levels correlated weakly with IN test CT and moderately with Russell's viper venom (RVV) test CT. Critically ill COVID-19 patients present with a high rate of LMWH resistance but with a variable LMWH response during their ICU stay. Therefore, LMWH–anti-Xa monitoring seems inevitable to achieve adequate target ranges. Furthermore, we propose the use of ClotPro's RVV test to assess the coagulation status during LMWH administration, as it correlates well with anti-Xa levels but more holistically reflects the coagulation cascade than anti-Xa activity alone. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
206. Predictive ability of viscoelastic testing using ClotPro® for short-term outcome in patients with severe Covid-19 ARDS with or without ECMO therapy: a retrospective study.
- Author
-
Heubner, Lars, Greiner, Marvin, Vicent, Oliver, Beyer-Westendorf, Jan, Tiebel, Oliver, Scholz, Ute, Güldner, Andreas, Mirus, Martin, Fries, Dietmar, Koch, Thea, and Spieth, Peter Markus
- Subjects
- *
ADULT respiratory distress syndrome treatment , *INTENSIVE care units , *CHEST (Anatomy) , *COVID-19 , *PREDICTIVE tests , *EXTRACORPOREAL membrane oxygenation , *THROMBELASTOGRAPHY , *RETROSPECTIVE studies , *ACQUISITION of data , *MANN Whitney U Test , *ADULT respiratory distress syndrome , *TREATMENT effectiveness , *ARTIFICIAL respiration , *HOSPITAL mortality , *COMPARATIVE studies , *MEDICAL records , *COMPUTED tomography , *ANGIOGRAPHY - Abstract
Background: SARS-CoV-2 infections are suspected to trigger the coagulation system through various pathways leading to a high incidence of thromboembolic complications, hypercoagulation and impaired fibrinolytic capacity were previously identified as potentially mechanisms. A reliable diagnostic tool for detecting both is still under discussion. This retrospective study is aimed to examine the prognostic relevance of early viscoelastic testing compared to conventional laboratory tests in COVID-19 patients with acute respiratory distress syndrome (ARDS). Methods: All mechanically ventilated patients with COVID-19 related ARDS treated in our intensive care unit (ICU) between January and March 2021 were included in this study. Viscoelastic testing (VET) was performed using the ClotPro® system after admission to our ICU. Prevalence of thromboembolic events was observed by standardized screening for venous and pulmonary thromboembolism using complete compression ultrasound and thoracic computed tomography pulmonary angiography at ICU admission, respectively. We examined associations between the severity of ARDS at admission to our ICU, in-hospital mortality and the incidence of thromboembolic events comparing conventional laboratory analysis and VET. ECMO related coagulopathy was investigated in a subgroup analysis. The data were analyzed using the Mann–Whitney U test. Results: Of 55 patients enrolled in this study, 22 patients required treatment with ECMO. Thromboembolic complications occurred in 51% of all patients. Overall hospital mortality was 55%. In patients with thromboembolic complications, signs of reduced fibrinolytic capacity could be detected in the TPA assay with prolonged lysis time, median 460 s (IQR 350–560) vs 359 s (IQR 287–521, p = 0.073). Patients with moderate to severe ARDS at admission to our ICU showed increased maximum clot firmness as a sign of hypercoagulation in the EX-test (70 vs 67 mm, p < 0.05), FIB-test (35 vs 24 mm, p < 0.05) and TPA-test (52 vs 36 mm, p < 0.05) as well as higher values of inflammatory markers (CRP, PCT and IL6). ECMO patients suffered more frequently from bleeding complications (32% vs 15%). Conclusion: Although, the predictive value for thromboembolic complications or mortality seems limited, point-of-care viscoelastic coagulation testing might be useful in detecting hypercoagulable states and impaired fibrinolysis in critically ill COVID-19 ARDS patients and could be helpful in identifying patients with a potentially very severe course of the disease. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
207. Impact of preoperative anemia, iron-deficiency and inflammation on survival after colorectal surgery—A retrospective cohort study.
- Author
-
Bath, Messina, Viveiros, André, Schaefer, Benedikt, Klein, Sebastian, Pammer, Lorenz M., Wagner, Sonja, Lorenz, Andreas, Rugg, Christopher, Gasser, Elisabeth, Ninkovic, Marijana, Panzer, Marlene, Pertler, Elke, Fries, Dietmar, Tilg, Herbert, Weiss, Guenter, Petzer, Verena, Öfner-Velano, Dietmar, and Zoller, Heinz
- Subjects
- *
IRON deficiency anemia , *PROCTOLOGY , *ANEMIA , *FERRITIN , *IRON supplements , *COHORT analysis , *C-reactive protein - Abstract
Background: Anemia is present in up to two-thirds of patients undergoing colorectal surgery mainly caused by iron deficiency and inflammation. As anemia is associated with increased risk of perioperative death, diagnosis and treatment of preoperative anemia according to etiology have been recommended. Objective: The aim of the present study was to assess if the association between anemia and survival in patients undergoing colorectal surgery was determined by the severity of anemia alone or also by anemia etiology. Methods: To determine the prevalence of anemia and etiology, preoperative hematological parameters, C-reactive protein, ferritin and transferrin saturation were retrospectively assessed and correlated with outcome in a cohort of patients undergoing colorectal surgery between 2005 and 2019 at the University Hospital of Innsbruck. Anemia was defined as hemoglobin <120 g/L in females and <130 g/L in males. The etiology of anemia was classified on the basis of serum iron parameters, as iron deficiency anemia, anemia of inflammation or other anemia etiologies. Results: Preoperative anemia was present in 54% (1316/2458) of all patients. Anemia was associated with iron deficiency in 45% (134/299) and classified as anemia of inflammation in 32% (97/299) of patients with available serum iron parameters. The etiology of anemia was a strong and independent predictor of survival, where iron deficiency and anemia of inflammation were associated with better postoperative survival than other anemia etiologies. One year survival rates were 84.3%, 77.3% and 69.1% for patients with iron deficiency anemia, anemia of inflammation and other anemia types. Inflammation indicated by high C-reactive protein is a strong negative predictor of overall survival. Conclusions: Anemia has a high prevalence among patients undergoing colorectal surgery and rational treatment requires early assessment of serum iron parameters and C-reactive protein. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
208. Administration of fibrinogen concentrate combined with prothrombin complex maintains hemostasis in children undergoing congenital heart repair (a long‐term propensity score‐matched study).
- Author
-
Velik‐Salchner, Corinna, Tauber, Helmuth, Rastner, Verena, Pajk, Werner, Mittermayr, Markus, Wally, Dieter, Kilo, Juliane, Vondrys, David, Fries, Dietmar, Fritz, Josef, and Streif, Werner
- Subjects
- *
PLASMA products , *PROTHROMBIN , *CARDIOPULMONARY bypass , *FIBRINOGEN , *BLOOD products , *CONGENITAL heart disease - Abstract
Background: Bleeding is a common problem in children with congenital heart disease undergoing major cardiac surgery requiring cardiopulmonary bypass (CPB). Little is known about optimal management with blood products. Objective: To investigate clinical outcome and hemostatic effects of fibrinogen concentrate (FC) in combination with prothrombin complex concentrate (PCC) versus standard treatment with fresh frozen plasma (FFP) in children undergoing cardiac surgery. Methods: For this single‐institution cohort study, data on 525 children were analyzed. Propensity score matching in 210 children was applied to reduce the impact of various baseline characteristics. Results: Three children treated with FC/PCC developed surgical site bleeding requiring surgical revision. One child developed central venous line‐related thrombosis. Blood loss through chest tube drainage was independent of FC/PCC. Coagulation abnormalities were not present in any of these children. Time to extubation and ICU stay did not differ. In the FC/PCC group, children received (median, Q1, Q3) 52 mg/kg (32, 83) FC and 28IU/kg (13, 44) PCC. Fibrinogen concentration was comparable at baseline. On admission to the ICU, fibrinogen was higher in children receiving FC/PCC, namely, 232 mg/dL (196, 280), than in children receiving FFP (186 mg/dL, 149, 224; P <.001). On discharge from the ICU, values did not differ ((FC/PCC 416 mg/dL (288, 501)), non‐FC/PCC 418 mg/dL (272, 585; P = 1.000)). Conclusion: FC/PCC was well tolerated and permitted hemostasis to be maintained, even in the very young. We were not able to detect a signal for inferiority of this treatment. We conclude that FC/PCC can safely replace FFP. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
209. Efficacy and safety of early target-controlled plasma volume replacement with a balanced gelatine solution versus a balanced electrolyte solution in patients with severe sepsis/septic shock: study protocol, design, and rationale of a prospective, randomized, controlled, double-blind, multicentric, international clinical trial : GENIUS-Gelatine use in ICU and sepsis.
- Author
-
Marx, Gernot, Zacharowski, Kai, Ichai, Carole, Asehnoune, Karim, Černý, Vladimír, Dembinski, Rolf, Ferrer Roca, Ricard, Fries, Dietmar, Molnar, Zsolt, Rosenberger, Peter, Sanchez-Sanchez, Manuel, Schürholz, Tobias, Dehnhardt, Tamara, Schmier, Sonja, von Kleist, Elke, Brauer, Ute, and Simon, Tim-Philipp
- Subjects
- *
BLOOD volume , *SEPTIC shock , *ELECTROLYTE solutions , *NEONATAL sepsis , *GELATIN , *RESEARCH protocols , *SEPSIS - Abstract
Background: Sepsis is associated with capillary leakage and vasodilatation and leads to hypotension and tissue hypoperfusion. Early plasma volume replacement is required to achieve haemodynamic stability (HDS) and maintain adequate tissue oxygenation. The right choice of fluids to be used for plasma volume replacement (colloid or crystalloid solutions) is still a matter of debate, and large trials investigating the use of colloid solutions containing gelatine are missing. This study aims to investigate the efficacy and safety of plasma volume replacement using either a combined gelatine-crystalloid regime (1:1 ratio) or a pure crystalloid regime.Methods: This is a prospective, controlled, randomized, double-blind, international, multicentric phase IV study with two parallel groups that is planned to be conducted at European intensive care units (ICUs) in a population of patients with hypovolaemia in severe sepsis/septic shock. A total of 608 eligible patients will be randomly assigned to receive either a gelatine-crystalloid regime (Gelaspan® 4% and Sterofundin® ISO, B. Braun Melsungen AG, in a 1:1 ratio) or a pure crystalloid regime (Sterofundin® ISO) for plasma volume replacement. The primary outcome is defined as the time needed to achieve HDS. Plasma volume replacement will be target-controlled, i.e. fluids will only be administered to volume-responsive patients. Volume responsiveness will be assessed through passive leg raising or fluid challenges. The safety and efficacy of both regimens will be assessed daily for 28 days or until ICU discharge (whichever occurs first) as the secondary outcomes of this study. Follow-up visits/calls will be scheduled on day 28 and day 90.Discussion: This study aims to generate evidence regarding which regimen-a gelatine-crystalloid regimen or a pure crystalloid regimen-is more effective in achieving HDS in critically ill patients with hypovolaemia. Study participants in both groups will benefit from the increased safety of target-controlled plasma volume replacement, which prevents fluid administration to already haemodynamically stable patients and reduces the risk of harmful fluid overload.Trial Registration: The European clinical trial database EudraCT 2015-000057-20 and the ClinicalTrials.gov Protocol Registration and Results System ClinicalTrials.gov NCT02715466 . Registered on 17 March 2016. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
210. Impaired fibrinolysis in critically ill COVID-19 patients.
- Author
-
Bachler, Mirjam, Bösch, Johannes, Stürzel, Daniel P., Hell, Tobias, Giebl, Andreas, Ströhle, Mathias, Klein, Sebastian J., Schäfer, Volker, Lehner, Georg F., Joannidis, Michael, Thomé, Claudius, and Fries, Dietmar
- Subjects
- *
COVID-19 , *CRITICALLY ill , *FIBRINOLYSIS , *BLOOD coagulation tests , *PLASMINOGEN activators - Abstract
Background: Critically ill coronavirus disease 2019 (COVID-19) patients present with a hypercoagulable state with high rates of macrovascular and microvascular thrombosis, for which hypofibrinolysis might be an important contributing factor.Methods: We retrospectively analysed 20 critically ill COVID-19 patients at Innsbruck Medical University Hospital whose coagulation function was tested with ClotPro® and compared with that of 60 healthy individuals at Augsburg University Clinic. ClotPro is a viscoelastic whole blood coagulation testing device. It includes the TPA test, which uses tissue factor (TF)-activated whole blood with added recombinant tissue-derived plasminogen activator (r-tPA) to induce fibrinolysis. For this purpose, the lysis time (LT) is measured as the time from when maximum clot firmness (MCF) is reached until MCF falls by 50%. We compared COVID-19 patients with prolonged LT in the TPA test and those with normal LT.Results: Critically ill COVID-19 patients showed hypercoagulability in ClotPro assays. MCF was higher in the EX test (TF-activated assay), IN test (ellagic acid-activated assay), and FIB test (functional fibrinogen assay) with decreased maximum lysis (ML) in the EX test (hypofibrinolysis) and highly prolonged TPA test LT (decreased fibrinolytic response), as compared with healthy persons. COVID-19 patients with decreased fibrinolytic response showed higher fibrinogen levels, higher thrombocyte count, higher C-reactive protein levels, and decreased ML in the EX test and IN test.Conclusion: Critically ill COVID-19 patients have impaired fibrinolysis. This hypofibrinolytic state could be at least partially dependent on a decreased fibrinolytic response. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
211. Antikoagulation beim Einsat extrakorporaler Verfahren
- Author
-
Kozek-Langenecker, Sibylle, Joannidis, Michael, Velik-Salchner, Corinna, Fries, Dietmar, editor, and Streif, Werner, editor
- Published
- 2014
- Full Text
- View/download PDF
212. Gerinnungsmanagement in der neurologischen und neurochirurgischen Intensivmedizin
- Author
-
Beer, Ronny, Steiner, Thorsten, Gruber, Andreas, Schmutzhard, Erich, Fries, Dietmar, editor, and Streif, Werner, editor
- Published
- 2014
- Full Text
- View/download PDF
213. Blutung beim Intensivpatienten – Transfusionen
- Author
-
Schennach, Harald, Fries, Dietmar, editor, and Streif, Werner, editor
- Published
- 2014
- Full Text
- View/download PDF
214. Diagnostik
- Author
-
Koscielny, Jürgen, Spannagl, Michael, Streif, Werner, Lang, Thomas, Kozek-Langenecker, Sibylle, Velik-Salchner, Corinna, Fries, Dietmar, editor, and Streif, Werner, editor
- Published
- 2014
- Full Text
- View/download PDF
215. Allgemeine Grundlagen der Gerinnungsphysiologie
- Author
-
Koscielny, Jürgen, Fries, Dietmar, editor, and Streif, Werner, editor
- Published
- 2014
- Full Text
- View/download PDF
216. Hämostaseologisch Relevantes aus der Geburtshilfe
- Author
-
Schlembach, Dietmar, Mörtl, Manfred, Fries, Dietmar, editor, and Streif, Werner, editor
- Published
- 2014
- Full Text
- View/download PDF
217. Gerinnungsmanagement beim pädiatrischen Intensivpatienten
- Author
-
Streif, Werner, Knöfler, Ralf, Fries, Dietmar, editor, and Streif, Werner, editor
- Published
- 2014
- Full Text
- View/download PDF
218. Efficacy of Argatroban in Critically Ill Patients with Heparin Resistance: A Retrospective Analysis.
- Author
-
Treichl, Benjamin, Bachler, Mirjam, Lorenz, Ingo, Friesenecker, Barbara, Oswald, Elgar, Schlimp, Christoph J., Pedross, Florian, and Fries, Dietmar
- Subjects
- *
CRITICALLY ill , *HEPARIN , *BLOOD coagulation , *THROMBOSIS , *DRUG resistance - Abstract
The patients who do not respond even to very high dosages of heparin are assumed to suffer from heparin resistance. The aim of this study was to investigate whether critically ill patients suffering from heparin resistance generally have low antithrombin III (AT) levels, and if the direct thrombin inhibitor argatroban in that case can be an effective option to achieve prophylactic anticoagulation. The study was conducted at the Department for General and Surgical Intensive Care Medicine at the University Hospital Innsbruck. We retrospectively included all patients between 2008 and 2012, who received argatroban because of poor response to high-dosage heparin prophylaxis. The period under observation lasted in total for 9 days, 2 days of anticoagulation with unfractionated heparin (UFH) and 7 days with argatroban. The primary objective was to investigate if after 7 (± 1) hours of switching to argatroban the activated partial thromboplastin time (aPTT) levels were in a prophylactic range of 45 to 55 seconds. Further objectives were to assess the AT level, side effects such as bleeding or thromboembolism, platelet count, correlation between organ function and argatroban dose as well as any need for allogeneic blood products. The study population, consisting of 5 women and 15 men with a mean (± standard deviation, SD) age of 54.6 ± 16.3 years, differed in many clinical aspects. A median (interquartile range) heparin dose of 1,000, 819 to 1,125 IU/h was administered for 2 days and failed in providing a prophylactic anticoagulation measured by the aPTT. The mean aPTT level with heparin treatment was 38.5 seconds (± 4.7) its change within that period was not significant. After switching to argatroban, the mean increase of the aPTT levels in all study patients amounted from 38.5 to 48.3 seconds (p < 0.001). The rise in aPTT clearly reaches sufficient prophylactic anticoagulant levels. The maintenance of prophylactic aPTT levels was achieved over the period of 1 week. There was neither a correlation found between low-AT levels and occurrence of heparin resistance, nor between the simplified acute physiology score II and the administered argatroban dose (r =--0.224, p = 0.342). The results of the present study indicate that argatroban is an effective alternative therapy, especially in critically ill patients, to achieve prophylactic anticoagulation when heparin resistance occurs. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
219. Tranexamsäure und Endoprothetik: zwischen „off label use" und „evidence-based medicine".
- Author
-
Lier, Heiko, Kammerer, Tobias, Knapp, Jürgen, Hofer, Stefan, Maegele, Marc, Fries, Dietmar, and von Heymann, Christian
- Published
- 2021
- Full Text
- View/download PDF
220. The exclusive use of coagulation factor concentrates enables reversal of coagulopathy and decreases transfusion rates in patients with major blunt trauma
- Author
-
Innerhofer, Petra, Westermann, Isabella, Tauber, Helmuth, Breitkopf, Robert, Fries, Dietmar, Kastenberger, Tobias, El Attal, Rene, Strasak, Alexander, and Mittermayr, Markus
- Subjects
- *
BLOOD coagulation factors , *BLUNT trauma , *BLOOD transfusion , *HEMORRHAGE , *ERYTHROCYTES , *BLOOD platelets , *HEMOSTASIS , *PATIENTS - Abstract
Abstract: Background: FFP and coagulation factor concentrates are used to correct trauma-induced coagulopathy (TIC). However, data on coagulation profiles investigating effects of therapy are scarce. Methods: This is an analysis of 144 patients with major blunt trauma ((ISS)≥15), who were enrolled in a prospective cohort study investigating characteristics and treatment of TIC. Patients who received fibrinogen concentrate and/or prothrombin complex concentrate alone (CF Group) were compared with those additionally receiving FFP transfusions (FFP Group). Results: Sixty-six patients exclusively received CF, while 78 patients additionally received FFP. Overall, patients were comparable regarding age, gender and ISS (CF Group, ISS 37 (29, 50); FFP Group ISS 38 (33, 55), p =0.28). Patients treated with CF alone showed sufficient haemostasis and received significantly fewer units of red blood cells (RBC) and platelets than did those also receiving FFP [(RBC 2(0, 4) U vs. 9 (5, 12) U; platelets 0 (0, 0) U vs. 1 (0, 2) U, p <0.001)]. In addition, fewer patients in the CF Group developed multiorgan failure (MOF) (18.2% vs. 37.2%, p =0.01) or sepsis (16.9% vs. 35.9%, p =0.014) than in the FFP Group. Propensity score-matching (n =28 pairs) used to reduce the impact of treatment selection confirmed that additional FFP administration showed no benefit in restoring haemostasis, but was associated with significantly higher transfusion rates for RBC and platelets. Conclusion: The use of CF alone effectively corrected coagulopathy in patients with severe blunt trauma and concomitantly decreased exposure to allogeneic transfusion, which may translate into improved outcome. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
221. Transfusion Approaches and Mortality in Trauma Patients: A Narrative Review
- Author
-
Dietmar Fries, Petra Innerhofer, Donat R. Spahn, University of Zurich, and Fries, Dietmar
- Subjects
medicine.medical_specialty ,10216 Institute of Anesthesiology ,2720 Hematology ,MEDLINE ,610 Medicine & health ,Hemorrhage ,030204 cardiovascular system & hematology ,2705 Cardiology and Cardiovascular Medicine ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Coagulopathy ,Humans ,Blood Transfusion ,Intensive care medicine ,Survival rate ,Hemostasis ,business.industry ,Mortality rate ,030208 emergency & critical care medicine ,Hematology ,medicine.disease ,Review article ,Survival Rate ,Damage control surgery ,Injury Severity Score ,Wounds and Injuries ,Narrative review ,Cardiology and Cardiovascular Medicine ,business - Abstract
Trauma is one of the leading causes of mortality in the world, accounting for millions of deaths per year. One of the most frequent causes of death in trauma patients is hemorrhage. The presence of a coagulopathy in trauma patients more than doubles the expected mortality. Coagulation management is a key aspect of care for bleeding trauma patients and has been investigated in many studies. However, it is unclear whether a particular approach to coagulation management is associated with a reduction in mortality. Treatment may be guided (e.g., viscoelastic test-guided administration of coagulation factor concentrates) or nonguided (e.g., treatment with a fixed ratio of plasma:red blood cells). This review aimed to assess the published literature regarding coagulation management technique and mortality rate. From the 41 articles obtained in the literature search, there appeared to be a trend toward lower mortality in studies utilizing a guided approach, despite a higher injury severity score in these patients. There were many methodological variations across studies including coagulation management approaches, inclusion criteria, time and type of measurements, use of early fast coagulation monitoring and damage control surgery principles, additional products to those under study, and potential regional differences. It is essential that controlled trials are performed to ascertain optimal transfusion approaches in trauma patients.
- Published
- 2017
222. Outcome of COVID-19 patients treated with VV-ECMO in Tyrol during the pandemic.
- Author
-
Peer A, Perschinka F, Lehner G, Mayerhöfer T, Mair P, Kilo J, Breitkopf R, Fries D, and Joannidis M
- Subjects
- Humans, Female, Male, Middle Aged, Aged, Austria epidemiology, Treatment Outcome, Hospital Mortality, Adult, Survival Rate, Intensive Care Units statistics & numerical data, SARS-CoV-2, Extracorporeal Membrane Oxygenation, COVID-19 mortality, COVID-19 therapy, Pandemics
- Abstract
Introduction: A small percentage of patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV‑2) showed severe respiratory deterioration requiring treatment with extracorporeal membrane oxygenation (ECMO). During the pandemic surges availability of ECMO devices was limited and resources had to be used wisely. The aim of this analysis was to determine the incidence and outcome of venovenous (VV) ECMO patients in Tyrol, when criteria based on the Extracorporeal Life Support Organization (ELSO) guidelines for VV-ECMO initiation were established., Methods: This is a secondary analysis of the Tyrol-CoV-ICU-Reg, which includes all patients admitted to an intensive care unit (ICU) during the coronavirus disease 2019 (COVID-19) pandemic in Tyrol. Of the 13 participating departments, VV-ECMO was performed at 4 units at the University Hospital Innsbruck., Results: Overall, 37 (3.4%) of 1101 patients were treated with VV-ECMO during their ICU stay. The hospital mortality rate was approximately 40% (n = 15). Multiorgan failure due to sepsis was the most common cause of death. No significant difference in survival rates between newly initiated and experienced centers was observed. The median survival time of nonsurvivors was 27 days (interquartile range, IQR: 22-36 days) after initiation of VV-ECMO. Acute kidney injury meeting the Kidney Disease: Improving Global Outcomes (KDIGO) criteria occurred in 48.6%. Renal replacement therapy (RRT) was initiated in 12 (32.4%) patients after a median of 18 days (IQR: 1-26 days) after VV-ECMO start. The median length of ICU and hospital stays were 38 days (IQR: 30-55 days) and 50 days (IQR: 37-83 days), respectively., Discussion: Despite a rapidly increased demand and the resulting requirement to initiate an additional ECMO center, we could demonstrate that a structured approach with interdisciplinary collaboration resulted in favorable survival rates similar to multinational reports., (© 2023. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
223. Hemoadsorption therapy for myoglobin removal in rhabdomyolysis: consensus of the hemoadsorption in rhabdomyolysis task force.
- Author
-
Forni L, Aucella F, Bottari G, Büttner S, Cantaluppi V, Fries D, Kielstein J, Kindgen-Milles D, Krenn C, Kribben A, Meiser A, Mitzner S, Ostermann M, Premuzic V, Rolfes C, Scharf C, Schunk S, Molnar Z, and Zarbock A
- Subjects
- Humans, Hemadsorption, Delphi Technique, Consensus, Rhabdomyolysis therapy, Myoglobin blood
- Abstract
Background: Rhabdomyolysis describes a syndrome characterized by muscle necrosis and the subsequent release of creatine kinase and myoglobin into the circulation. Myoglobin elimination with extracorporeal hemoadsorption has been shown to effectively remove myoglobin from the circulation. Our aim was to provide best practice consensus statements developed by the Hemoadsorption in Rhabdomyolysis Task Force (HRTF) regarding the use of hemadsorption for myoglobin elimination., Methods: A systematic literature search was performed until 11th of January 2023, after which the Rhabdomyolysis RTF was assembled comprising international experts from 6 European countries. Online conferences were held between 18th April - 4th September 2023, during which 37 consensus questions were formulated and using the Delphi process, HRTF members voted online on an anonymised platform. In cases of 75 to 90% agreement a second round of voting was performed., Results: Using the Delphi process on the 37 questions, strong consensus (> 90% agreement) was achieved in 12, consensus (75 to 90% agreement) in 10, majority (50 to 74%) agreement in 13 and no consensus (< 50% agreement) in 2 cases. The HRTF formulated the following recommendations: (1) Myoglobin contributes to the development of acute kidney injury; (2) Patients with myoglobin levels of > 10,000 ng/ml should be considered for extracorporeal myoglobin removal by hemoadsorption; (3) Hemoadsorption should ideally be started within 24 h of admission; (4) If myoglobin cannot be measured then hemoadsorption may be indicated based on clinical picture and creatinine kinase levels; (5) Cartridges should be replaced every 8-12 h until myoglobin levels < 10,000 ng/ml; (6) In patients with acute kidney injury, hemoadsorption can be discontinued before dialysis is terminated and should be maintained until the myoglobin concentration values are consistently < 5000 ng/ml., Conclusions: The current consensus of the HRTF support that adjuvant hemoadsorption therapy in severe rhabdomyolysis is both feasible and safe and may be an effective method to reduce elevated circulating levels of myoglobin., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
224. Clinical practice, research, and collaboration with industry: impact of the discontinuation of a critical device.
- Author
-
Fries D, Gratz J, Asmis L, Groene P, Heubner L, Schmitt F, and Schöchl H
- Subjects
- Humans, Industry, Critical Care methods, Biomedical Research
- Published
- 2024
- Full Text
- View/download PDF
225. Prehospital transfusion of allogeneic blood products.
- Author
-
Alomar-Dominguez C, Bösch J, and Fries D
- Subjects
- Humans, Blood Transfusion, Hemorrhage etiology, Hemorrhage prevention & control, Blood Coagulation Disorders etiology, Blood Coagulation Disorders therapy, Emergency Medical Services, Hematopoietic Stem Cell Transplantation, Wounds and Injuries
- Abstract
Purpose of Review: The purpose of this article is to provide a structural and practical analysis of the currently available data concerning prehospital transfusion of allogeneic blood products in cases of trauma and severe bleeding., Recent Findings: Prehospital transfusion of allogeneic blood products is a very early intervention, which may offer the potential to improve outcome, but that also comes with challenges including resource allocation, blood product storage, logistics, patient selection, legal and ethical considerations, adverse effects, and costs. Potential benefits including improved stability and reduction in coagulopathy and blood loss have not yet been clearly demonstrated., Summary: The questionable efficacy and challenges in clinical practice may outweigh the potential benefits of prehospital allogeneic transfusion., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
226. Thrombosis prophylaxis following trauma.
- Author
-
Bösch J, Bachler M, and Fries D
- Subjects
- Humans, Anticoagulants therapeutic use, Heparin therapeutic use, Heparin, Low-Molecular-Weight therapeutic use, Thrombosis prevention & control, Venous Thromboembolism etiology, Wounds and Injuries complications, Wounds and Injuries drug therapy
- Abstract
Purpose of Review: This review explores the persistent occurrence of venous thromboembolic events (VTE) in major trauma patients despite standard thrombosis prophylaxis with low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH). It investigates the inadequacies of standard pharmacologic prophylaxis and proposes alternative approaches not covered in current trauma guidelines., Recent Findings: Recent studies highlight the effectiveness of monitoring and adjusting subcutaneous LMWH doses based on anti-Xa levels for the purpose of reducing VTE in trauma patients. The need for dose adaptation arises due to factors like fluctuating organ function, varying antithrombin levels, interaction with plasma proteins, and altered bioavailability influenced by oedema or vasopressor use. Additionally, promising alternatives such as intravenous LMWH, UFH, and argatroban have shown success in intensive care settings., Summary: The standard dosing of subcutaneous LMWH is often insufficient for effective thrombosis prophylaxis in trauma patients. A more personalised approach, adjusting doses based on specific effect levels like anti-Xa or choosing an alternative mode of anticoagulation, could reduce the risk of insufficient prophylaxis and subsequent VTE., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
227. Incidence, risk factors and outcome of acute kidney injury in critically ill COVID-19 patients in Tyrol, Austria: a prospective multicenter registry study.
- Author
-
Mayerhöfer T, Perschinka F, Klein SJ, Peer A, Lehner GF, Bellmann R, Gasteiger L, Mittermayr M, Breitkopf R, Eschertzhuber S, Mathis S, Fiala A, Fries D, Ströhle M, Foidl E, Hasibeder W, Helbok R, Kirchmair L, Stögermüller B, Krismer C, Heiner T, Ladner E, Thomé C, Preuß-Hernandez C, Mayr A, Potocnik M, Reitter B, Brunner J, Zagitzer-Hofer S, Ribitsch A, and Joannidis M
- Subjects
- Adult, Aged, Humans, Austria epidemiology, Critical Illness therapy, Incidence, Intensive Care Units, Pandemics, Respiration, Artificial, Retrospective Studies, Risk Factors, SARS-CoV-2, Middle Aged, Acute Kidney Injury epidemiology, Acute Kidney Injury therapy, COVID-19 complications, COVID-19 epidemiology, COVID-19 therapy
- Abstract
Introduction: Acute kidney injury is a frequent complication in critically ill patients with and without COVID-19. The aim of this study was to evaluate the incidence of, and risk factors for, acute kidney injury and its effect on clinical outcomes of critically ill COVID-19 patients in Tyrol, Austria., Methods: This multicenter prospective registry study included adult patients with a SARS-CoV-2 infection confirmed by polymerase chain reaction, who were treated in one of the 12 dedicated intensive care units during the COVID-19 pandemic from February 2020 until May 2022., Results: In total, 1042 patients were included during the study period. The median age of the overall cohort was 66 years. Of the included patients, 267 (26%) developed acute kidney injury during their intensive care unit stay. In total, 12.3% (n = 126) required renal replacement therapy with a median duration of 9 (IQR 3-18) days. In patients with acute kidney injury the rate of invasive mechanical ventilation was significantly higher with 85% (n = 227) compared to 41% (n = 312) in the no acute kidney injury group (p < 0.001). The most important risk factors for acute kidney injury were invasive mechanical ventilation (OR = 4.19, p < 0.001), vasopressor use (OR = 3.17, p < 0.001) and chronic kidney disease (OR = 2.30, p < 0.001) in a multivariable logistic regression analysis. Hospital and intensive care unit mortality were significantly higher in patients with acute kidney injury compared to patients without acute kidney injury (Hospital mortality: 52.1% vs. 17.2%, p < 0.001, ICU-mortality: 47.2% vs. 14.7%, p < 0.001)., Conclusion: As in non-COVID-19 patients, acute kidney injury is clearly associated with increased mortality in critically ill COVID-19 patients. Among known risk factors, invasive mechanical ventilation has been identified as an independent and strong predictor of acute kidney injury., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
228. Safety of interhospital transfer for critically ill COVID-19 patients.
- Author
-
Perschinka F, Niedermoser H, Peer A, Lehner GF, Mayerhöfer T, Stöllnberger V, Fries D, and Joannidis M
- Subjects
- Humans, Transportation of Patients, Critical Care, Patient Transfer, Critical Illness therapy, COVID-19
- Published
- 2023
- Full Text
- View/download PDF
229. Management of severe peri-operative bleeding: Guidelines from the European Society of Anaesthesiology and Intensive Care: Second update 2022.
- Author
-
Kietaibl S, Ahmed A, Afshari A, Albaladejo P, Aldecoa C, Barauskas G, De Robertis E, Faraoni D, Filipescu DC, Fries D, Godier A, Haas T, Jacob M, Lancé MD, Llau JV, Meier J, Molnar Z, Mora L, Rahe-Meyer N, Samama CM, Scarlatescu E, Schlimp C, Wikkelsø AJ, and Zacharowski K
- Subjects
- Humans, Critical Care, Blood Loss, Surgical, Awareness, Consensus, Anesthesiology
- Abstract
Background: Management of peri-operative bleeding is complex and involves multiple assessment tools and strategies to ensure optimal patient care with the goal of reducing morbidity and mortality. These updated guidelines from the European Society of Anaesthesiology and Intensive Care (ESAIC) aim to provide an evidence-based set of recommendations for healthcare professionals to help ensure improved clinical management., Design: A systematic literature search from 2015 to 2021 of several electronic databases was performed without language restrictions. Grading of Recommendations, Assessment, Development and Evaluation (GRADE) was used to assess the methodological quality of the included studies and to formulate recommendations. A Delphi methodology was used to prepare a clinical practice guideline., Results: These searches identified 137 999 articles. All articles were assessed, and the existing 2017 guidelines were revised to incorporate new evidence. Sixteen recommendations derived from the systematic literature search, and four clinical guidances retained from previous ESAIC guidelines were formulated. Using the Delphi process on 253 sentences of guidance, strong consensus (>90% agreement) was achieved in 97% and consensus (75 to 90% agreement) in 3%., Discussion: Peri-operative bleeding management encompasses the patient's journey from the pre-operative state through the postoperative period. Along this journey, many features of the patient's pre-operative coagulation status, underlying comorbidities, general health and the procedures that they are undergoing need to be taken into account. Due to the many important aspects in peri-operative nontrauma bleeding management, guidance as to how best approach and treat each individual patient are key. Understanding which therapeutic approaches are most valuable at each timepoint can only enhance patient care, ensuring the best outcomes by reducing blood loss and, therefore, overall morbidity and mortality., Conclusion: All healthcare professionals involved in the management of patients at risk for surgical bleeding should be aware of the current therapeutic options and approaches that are available to them. These guidelines aim to provide specific guidance for bleeding management in a variety of clinical situations., (Copyright © 2023 European Society of Anaesthesiology and Intensive Care. Unauthorized reproduction of this article is prohibited.)
- Published
- 2023
- Full Text
- View/download PDF
230. Thromboprophylaxis with argatroban in critically ill patients with sepsis: a review.
- Author
-
Bachler M, Asmis LM, Koscielny J, Lang T, Nowak H, Paulus P, Schewe JC, von Heymann C, and Fries D
- Subjects
- Anticoagulants adverse effects, Arginine analogs & derivatives, Critical Illness, Heparin adverse effects, Heparin, Low-Molecular-Weight therapeutic use, Humans, Pipecolic Acids, Sulfonamides, COVID-19, Sepsis drug therapy, Thrombocytopenia chemically induced, Thrombosis drug therapy, Thrombosis etiology, Thrombosis prevention & control, Venous Thromboembolism drug therapy
- Abstract
During sepsis, an initial prothrombotic shift takes place, in which coagulatory acute-phase proteins are increased, while anticoagulatory factors and platelet count decrease. Further on, the fibrinolytic system becomes impaired, which contributes to disease severity. At a later stage in sepsis, coagulation factors may become depleted, and sepsis patients may shift into a hypo-coagulable state with an increased bleeding risk. During the pro-coagulatory shift, critically ill patients have an increased thrombosis risk that ranges from developing micro-thromboses that impair organ function to life-threatening thromboembolic events. Here, thrombin plays a key role in coagulation as well as in inflammation. For thromboprophylaxis, low molecular weight heparins (LMWH) and unfractionated heparins (UFHs) are recommended. Nevertheless, there are conditions such as heparin resistance or heparin-induced thrombocytopenia (HIT), wherein heparin becomes ineffective or even puts the patient at an increased prothrombotic risk. In these cases, argatroban, a direct thrombin inhibitor (DTI), might be a potential alternative anticoagulatory strategy. Yet, caution is advised with regard to dosing of argatroban especially in sepsis. Therefore, the starting dose of argatroban is recommended to be low and should be titrated to the targeted anticoagulation level and be closely monitored in the further course of treatment. The authors of this review recommend using DTIs such as argatroban as an alternative anticoagulant in critically ill patients suffering from sepsis or COVID-19 with suspected or confirmed HIT, HIT-like conditions, impaired fibrinolysis, in patients on extracorporeal circuits and patients with heparin resistance, when closely monitored., (Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2022
- Full Text
- View/download PDF
231. Point of care coagulation management in anesthesiology and critical care.
- Author
-
Heubner L, Mirus M, Vicent O, Güldner A, Tiebel O, Beyer-Westendorf J, Fries D, and Spieth PM
- Subjects
- Blood Coagulation, Critical Care, Humans, Reproducibility of Results, Anesthesiology, Point-of-Care Systems
- Abstract
Point of care (POC) devices are increasingly used in the ICU and in anesthesia. Besides POC-devices for blood gas analysis, several devices are available for coagulation measurements. Although basic principles for thromboelastographic measurements are not novel, some promising developments were made during the last decade improving both user-friendliness and measurement reliability. For instance, POC measurements of activated clotting time (ACT) for heparin monitoring is still regarded as standard-of-care in cardiac interventions and surgery. In the field of anesthesia and intensive care medicine, POC-devices for thromboelastographic and platelet aggregation measurements are widely used. Their impact in case of bleeding and patient blood management for cardiothoracic and trauma surgery is well known. Moreover, there are promising concepts for anticoagulation monitoring including new oral anticoagulant drugs. Coagulation POC-devices may also identify patients at specific risk for thromboembolic events quickly. On the other hand, benefits of POC-devices need to be balanced against limitations, which include technical restrictions and operator related errors, mainly affecting reproducibility and interpretation of results. Therefore, it is recommendable to consider results of POC-coagulation testing in comparison to standard laboratory tests (SLT). Nevertheless, in urgent or emergency situations POC results enable fast decision making to optimize patient care.
- Published
- 2022
- Full Text
- View/download PDF
232. [Standard administration of tranexamic acid for prophylaxis in endoprosthetics: a good idea?]
- Author
-
Lier H, Kammerer T, Knapp J, Hofer S, Maegele M, Fries D, and von Heymann C
- Subjects
- Blood Loss, Surgical prevention & control, Humans, Antifibrinolytic Agents therapeutic use, Plastic Surgery Procedures, Tranexamic Acid therapeutic use
- Published
- 2022
- Full Text
- View/download PDF
233. Variations and obstacles in the use of coagulation factor concentrates for major trauma bleeding across Europe: outcomes from a European expert meeting.
- Author
-
Černý V, Maegele M, Agostini V, Fries D, Leal-Noval SR, Nardai G, Nardi G, Östlund A, and Schöchl H
- Subjects
- Blood Coagulation Factors pharmacology, Blood Coagulation Factors therapeutic use, Fibrinogen therapeutic use, Hemorrhage drug therapy, Hemorrhage etiology, Humans, Blood Coagulation Disorders therapy, Hemostatics therapeutic use, Tranexamic Acid therapeutic use
- Abstract
Purpose: Trauma is a leading cause of mortality, with major bleeding and trauma-induced coagulopathy (TIC) contributing to negative patient outcomes. Treatments for TIC include tranexamic acid (TXA), fresh frozen plasma (FFP), and coagulation factor concentrates (CFCs, e.g. prothrombin complex concentrates [PCCs] and fibrinogen concentrate [FCH]). Guidelines for TIC management vary across Europe and a clear definition of TIC is still lacking., Methods: An advisory board involving European trauma experts was held on 02 February 2019, to discuss clinical experience in the management of trauma-related bleeding and recommendations from European guidelines, focusing on CFC use (mainly FCH). This review summarises the discussions, including TIC definitions, gaps in the guidelines that affect their implementation, and barriers to use of CFCs, with suggested solutions., Results: A definition of TIC, which incorporates clinical (e.g. severe bleeding) and laboratory parameters (e.g. low fibrinogen) is suggested. TIC should be treated immediately with TXA and FCH/red blood cells; subsequently, if fibrinogen ≤ 1.5 g/L (or equivalent by viscoelastic testing), treatment with FCH, then PCC (if bleeding continues) is suggested. Fibrinogen concentrate, and not FFP, should be administered as first-line therapy for TIC. Several initiatives may improve TIC management, with improved medical education of major importance; generation of new and stronger data, simplified clinical practice guidance, and improved access to viscoelastic testing are also critical factors., Conclusions: Management of TIC is challenging. A standard definition of TIC, together with initiatives to facilitate effective CFC administration, may contribute to improved patient care and outcomes., (© 2021. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
234. Hypothermia Induced Impairment of Platelets: Assessment With Multiplate vs. ROTEM-An In Vitro Study.
- Author
-
Wallner B, Schenk B, Paal P, Falk M, Strapazzon G, Martini WZ, Brugger H, and Fries D
- Abstract
Introduction: This experimental in vitro study aimed to identify and characterize hypothermia-associated coagulopathy and to compare changes in mild to severe hypothermia with the quantitative measurement of rotational thromboelastometry (ROTEM) and multiple-electrode aggregometry (MULTIPLATE). Methods: Whole blood samples from 18 healthy volunteers were analyzed at the target temperatures of 37, 32, 24, 18, and 13.7°C with ROTEM (ExTEM, InTEM and FibTEM) and MULTIPLATE using the arachidonic acid 0.5 mM (ASPI), thrombin receptor-activating peptide-6 32 µM (TRAP) and adenosine diphosphate 6.4 µM (ADP) tests at the corresponding incubating temperatures for coagulation assessment. Results: Compared to baseline (37°C) values ROTEM measurements of clotting time (CT) was prolonged by 98% (at 18°C), clot formation time (CFT) was prolonged by 205% and the alpha angle dropped to 76% at 13.7°C ( p < 0.001). At 24.0°C CT was prolonged by 56% and CFT by 53%. Maximum clot firmness was only slightly reduced by ≤2% at 13.7°C. Platelet function measured by MULTIPLATE was reduced with decreasing temperature ( p < 0.001): AUC at 13.7°C -96% (ADP), -92% (ASPI) and -91% (TRAP). Conclusion: Hypothermia impairs coagulation by prolonging coagulation clotting time and by decreasing the velocity of clot formation in ROTEM measurements. MULTIPLATE testing confirms a linear decrease in platelet function with decreasing temperatures, but ROTEM fails to adequately detect hypothermia induced impairment of platelets., Competing Interests: BS was employed by the company Alexion Pharma Austria GmbH, Wien, Austria. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Wallner, Schenk, Paal, Falk, Strapazzon, Martini, Brugger and Fries.)
- Published
- 2022
- Full Text
- View/download PDF
235. The impact of acquired coagulation factor XIII deficiency in traumatic bleeding and wound healing.
- Author
-
Kleber C, Sablotzki A, Casu S, Olivieri M, Thoms KM, Horter J, Schmitt FCF, Birschmann I, Fries D, Maegele M, Schöchl H, and Wilhelmi M
- Subjects
- Factor XIII metabolism, Factor XIII therapeutic use, Hemorrhage drug therapy, Humans, Wound Healing, Blood Coagulation Disorders etiology, Factor XIII Deficiency complications, Factor XIII Deficiency diagnosis, Factor XIII Deficiency drug therapy
- Abstract
Factor XIII (FXIII) is a protein involved in blood clot stabilisation which also plays an important role in processes including trauma, wound healing, tissue repair, pregnancy, and even bone metabolism. Following surgery, low FXIII levels have been observed in patients with peri-operative blood loss and FXIII administration in those patients was associated with reduced blood transfusions. Furthermore, in patients with low FXIII levels, FXIII supplementation reduced the incidence of post-operative complications including disturbed wound healing. Increasing awareness of potentially low FXIII levels in specific patient populations could help identify patients with acquired FXIII deficiency; although opinions and protocols vary, a cut-off for FXIII activity of ~ 60-70% may be appropriate to diagnose acquired FXIII deficiency and guide supplementation. This narrative review discusses altered FXIII levels in trauma, surgery and wound healing, diagnostic approaches to detect FXIII deficiency and clinical guidance for the treatment of acquired FXIII deficiency., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
236. The Influence of Environmental Hypoxia on Hemostasis-A Systematic Review.
- Author
-
Treml B, Wallner B, Blank C, Fries D, and Schobersberger W
- Abstract
Humans have been ascending to high altitudes for centuries, with a growing number of professional- and leisure-related sojourns occurring in this millennium. A multitude of scientific reports on hemostatic disorders at high altitude suggest that hypoxia is an independent risk factor. However, no systematic analysis of the influence of environmental hypoxia on coagulation, fibrinolysis and platelet function has been performed. To fill this gap, we performed a systematic literature review, including only the data of healthy persons obtained during altitude exposure (<60 days). The results were stratified by the degree of hypoxia and sub-categorized into active and passive ascents and sojourns. Twenty-one studies including 501 participants were included in the final analysis. Since only one study provided relevant data, no conclusions regarding moderate altitudes (1,500-2,500 m) could be drawn. At high altitude (2,500-5,400 m), only small pathophysiological changes were seen, with a possible impact of increasing exercise loads. Elevated thrombin generation seems to be balanced by decreased platelet activation. Viscoelastic methods do not support increased thrombogenicity, with fibrinolysis being unaffected by high altitude. At extreme altitude (5,400-8,850 m), the limited data showed activation of coagulation in parallel with stimulation of fibrinolysis. Furthermore, multiple confounding variables at altitude, like training status, exercise load, fluid status and mental stress, prevent definitive conclusions being drawn on the impact of hypoxia on hemostasis. Thus, we cannot support the hypothesis that hypoxia triggers hypercoagulability and increases the risk of thromboembolic disorders, at least in healthy sojourners., Competing Interests: CB and WS were employed by Private University for Health Sciences, Medical Informatics and Technology UMIT, Hall i.T. and Tirol Kliniken GmbH. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Treml, Wallner, Blank, Fries and Schobersberger.)
- Published
- 2022
- Full Text
- View/download PDF
237. Changes in characteristics and outcomes of critically ill COVID-19 patients in Tyrol (Austria) over 1 year.
- Author
-
Mayerhöfer T, Klein SJ, Peer A, Perschinka F, Lehner GF, Hasslacher J, Bellmann R, Gasteiger L, Mittermayr M, Eschertzhuber S, Mathis S, Fiala A, Fries D, Kalenka A, Foidl E, Hasibeder W, Helbok R, Kirchmair L, Stögermüller B, Krismer C, Heiner T, Ladner E, Thomé C, Preuß-Hernandez C, Mayr A, Pechlaner A, Potocnik M, Reitter B, Brunner J, Zagitzer-Hofer S, Ribitsch A, and Joannidis M
- Subjects
- Aged, Austria, Critical Illness, Humans, Intensive Care Units, Middle Aged, Pandemics, Respiration, Artificial, Retrospective Studies, SARS-CoV-2, COVID-19
- Abstract
Background: Widely varying mortality rates of critically ill Coronavirus disease 19 (COVID-19) patients in the world highlighted the need for local surveillance of baseline characteristics, treatment strategies and outcome. We compared two periods of the COVID-19 pandemic to identify important differences in characteristics and therapeutic measures and their influence on the outcome of critically ill COVID-19 patients., Methods: This multicenter prospective register study included all patients with a SARS-CoV‑2 infection confirmed by polymerase chain reaction, who were treated in 1 of the 12 intensive care units (ICU) from 8 hospitals in Tyrol, Austria during 2 defined periods (1 February 2020 until 17 July: first wave and 18 July 2020 until 22 February 2021: second wave) of the COVID-19 pandemic., Results: Overall, 508 patients were analyzed. The majority (n = 401) presented during the second wave, where the median age was significantly higher (64 years, IQR 54-74 years vs. 72 years, IQR 62-78 years, p < 0.001). Invasive mechanical ventilation was less frequent during the second period (50.5% vs 67.3%, p = 0.003), as was the use of vasopressors (50.3% vs. 69.2%, p = 0.001) and renal replacement therapy (12.0% vs. 19.6%, p = 0.061), which resulted in shorter ICU length of stay (10 days, IQR 5-18 days vs. 18 days, IQR 5-31 days, p < 0.001). Nonetheless, ICU mortality did not change (28.9% vs. 21.5%, p = 0.159) and hospital mortality even increased (22.4% vs. 33.4%, p = 0.039) in the second period. Age, frailty and the number of comorbidities were significant predictors of hospital mortality in a multivariate logistic regression analysis of the overall cohort., Conclusion: Advanced treatment strategies and learning effects over time resulted in reduced rates of mechanical ventilation and vasopressor use in the second wave associated with shorter ICU length of stay. Despite these improvements, age appears to be a dominant factor for hospital mortality in critically ill COVID-19 patients., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
238. Efficacy of prehospital administration of fibrinogen concentrate in trauma patients bleeding or presumed to bleed (FIinTIC): A multicentre, double-blind, placebo-controlled, randomised pilot study.
- Author
-
Ziegler B, Bachler M, Haberfellner H, Niederwanger C, Innerhofer P, Hell T, Kaufmann M, Maegele M, Martinowitz U, Nebl C, Oswald E, Schöchl H, Schenk B, Thaler M, Treichl B, Voelckel W, Zykova I, Wimmer C, and Fries D
- Subjects
- Adolescent, Adult, Austria, Czech Republic, Germany, Humans, Pilot Projects, Prospective Studies, Emergency Medical Services, Fibrinogen
- Abstract
Background: Trauma-induced coagulopathy (TIC) substantially contributes to mortality in bleeding trauma patients., Objective: The aim of the study was to administer fibrinogen concentrate in the prehospital setting to improve blood clot stability in trauma patients bleeding or presumed to bleed., Design: A prospective, randomised, placebo-controlled, double-blinded, international clinical trial., Setting: This emergency care trial was conducted in 12 Helicopter Emergency Medical Services (HEMS) and Emergency Doctors' vehicles (NEF or NAW) and four trauma centres in Austria, Germany and Czech Republic between 2011 and 2015., Patients: A total of 53 evaluable trauma patients aged at least 18 years with major bleeding and in need of volume therapy were included, of whom 28 received fibrinogen concentrate and 25 received placebo., Interventions: Patients were allocated to receive either fibrinogen concentrate or placebo prehospital at the scene or during transportation to the study centre., Main Outcome Measures: Primary outcome was the assessment of clot stability as reflected by maximum clot firmness in the FIBTEM assay (FIBTEM MCF) before and after administration of the study drug., Results: Median FIBTEM MCF decreased in the placebo group between baseline (before administration of study treatment) and admission to the Emergency Department, from a median of 12.5 [IQR 10.5 to 14] mm to 11 [9.5 to 13] mm (P = 0.0226), but increased in the FC Group from 13 [11 to 15] mm to 15 [13.5 to 17] mm (P = 0.0062). The median between-group difference in the change in FIBTEM MCF was 5 [3 to 7] mm (P < 0.0001). Median fibrinogen plasma concentrations in the fibrinogen concentrate Group were kept above the recommended critical threshold of 2.0 g l-1 throughout the observation period., Conclusion: Early fibrinogen concentrate administration is feasible in the complex and time-sensitive environment of prehospital trauma care. It protects against early fibrinogen depletion, and promotes rapid blood clot initiation and clot stability., Trial Registry Numbers: EudraCT: 2010-022923-31 and ClinicalTrials.gov: NCT01475344., (Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Society of Anaesthesiology.)
- Published
- 2021
- Full Text
- View/download PDF
239. Modern methods for monitoring hemorrhagic resuscitation in the United States: Why the delay?
- Author
-
Walsh M, Thomas S, Kwaan H, Aversa J, Anderson S, Sundararajan R, Zimmer D, Bunch C, Stillson J, Draxler D, Balogh ZJ, and Fries D
- Subjects
- Hemorrhage therapy, Humans, Resuscitation, Thrombelastography, United States epidemiology, Practice Management, Shock, Hemorrhagic therapy
- Published
- 2020
- Full Text
- View/download PDF
240. Structured ICU resource management in a pandemic is associated with favorable outcome in critically ill COVID‑19 patients.
- Author
-
Klein SJ, Bellmann R, Dejaco H, Eschertzhuber S, Fries D, Furtwängler W, Gasteiger L, Hasibeder W, Helbok R, Hochhold C, Hofer S, Kirchmair L, Krismer C, Ladner E, Lehner GF, Mathis S, Mayr A, Mittermayr M, Peer A, Preuß Hernández C, Reitter B, Ströhle M, Swoboda M, Thomé C, and Joannidis M
- Subjects
- Aged, Austria, COVID-19, Cohort Studies, Critical Illness therapy, Female, Humans, Intensive Care Units, Male, Middle Aged, SARS-CoV-2, Treatment Outcome, Betacoronavirus, Coronavirus Infections therapy, Pandemics, Pneumonia, Viral therapy
- Abstract
Introduction: On February 25, 2020, the first 2 patients were tested positive for severe acute respiratory syndrome coronavirus‑2 (SARS-CoV-2) in Tyrol, Austria. Rapid measures were taken to ensure adequate intensive care unit (ICU) preparedness for a surge of critically ill coronavirus disease-2019 (COVID-19) patients., Methods: This cohort study included all COVID-19 patients admitted to an ICU with confirmed or strongly suspected COVID-19 in the State of Tyrol, Austria. Patients were recorded in the Tyrolean COVID-19 intensive care registry. Date of final follow-up was July 17, 2020., Results: A total of 106 critically ill patients with COVID-19 were admitted to 1 of 13 ICUs in Tyrol from March 9 to July 17, 2020. Median age was 64 years (interquartile range, IQR 54-74 years) and the majority of patients were male (76 patients, 71.7%). Median simplified acute physiology score III (SAPS III) was 56 points (IQR 49-64 points). The median duration from appearance of first symptoms to ICU admission was 8 days (IQR 5-11 days). Invasive mechanical ventilation was required in 72 patients (67.9%) and 6 patients (5.6%) required extracorporeal membrane oxygenation treatment. Renal replacement therapy was necessary in 21 patients (19.8%). Median ICU length of stay (LOS) was 18 days (IQR 5-31 days), median hospital LOS was 27 days (IQR 13-49 days). The ICU mortality was 21.7% (23 patients), hospital mortality was 22.6%. There was no significant difference in ICU mortality in patients receiving invasive mechanical ventilation and in those not receiving it (18.1% vs. 29.4%, p = 0.284). As of July 17th, 2020, two patients are still hospitalized, one in an ICU, one on a general ward., Conclusion: Critically ill COVID-19 patients in Tyrol showed high severity of disease often requiring complex treatment with increased lengths of ICU and hospital stay. Nevertheless, the mortality was found to be remarkably low, which may be attributed to our adaptive surge response providing sufficient ICU resources.
- Published
- 2020
- Full Text
- View/download PDF
241. Unrecognized diabetes in critically ill COVID-19 patients.
- Author
-
Klein SJ, Fries D, Kaser S, Mathis S, Thomé C, and Joannidis M
- Subjects
- Aged, COVID-19, Critical Illness, Diabetes Mellitus diagnosis, Female, Humans, Male, Middle Aged, Pandemics, Coronavirus Infections epidemiology, Coronavirus Infections therapy, Diabetes Mellitus epidemiology, Pneumonia, Viral epidemiology, Pneumonia, Viral therapy
- Published
- 2020
- Full Text
- View/download PDF
242. A Prospective Pilot Trial to Assess the Efficacy of Argatroban (Argatra ® ) in Critically Ill Patients with Heparin Resistance.
- Author
-
Bachler M, Hell T, Bösch J, Treml B, Schenk B, Treichl B, Friesenecker B, Lorenz I, Stengg D, Hruby S, Wallner B, Oswald E, Ströhle M, Niederwanger C, Irsara C, and Fries D
- Abstract
The current study aims to evaluate whether prophylactic anticoagulation using argatroban or an increased dose of unfractionated heparin (UFH) is effective in achieving the targeted activated partial thromboplastin time (aPTT) of more than 45 s in critically ill heparin-resistant (HR) patients. Patients were randomized either to continue receiving an increased dose of UFH, or to be treated with argatroban. The endpoints were defined as achieving an aPTT target of more than 45 s at 7 h and 24 h. This clinical trial was registered on clinicaltrials.gov (NCT01734252) and on EudraCT (2012-000487-23). A total of 42 patients, 20 patients in the heparin and 22 in the argatroban group, were included. Of the patients with continued heparin treatment 55% achieved the target aPTT at 7 h, while only 40% of this group maintained the target aPTT after 24 h. Of the argatroban group 59% reached the target aPTT at 7 h, while at 24 h 86% of these patients maintained the targeted aPTT. Treatment success at 7 h did not differ between the groups ( p = 0.1000), whereas at 24 h argatroban showed significantly greater efficacy ( p = 0.0021) than did heparin. Argatroban also worked better in maintaining adequate anticoagulation in the further course of the study. There was no significant difference in the occurrence of bleeding or thromboembolic complications between the treatment groups. In the case of heparin-resistant critically ill patients, argatroban showed greater efficacy than did an increased dose of heparin in achieving adequate anticoagulation at 24 h and in maintaining the targeted aPTT goal throughout the treatment phase., Competing Interests: Mirjam Bachler has received research funding and travel grants from LFB Biomedicaments, Baxter GmbH, CSL Behring GmbH, and Mitsubishi Tanabe, as well as non-financial support from TEM International outside the submitted work. Benedikt Treml has received travel grants from Pfizer. Bettina Schenk has received travel grants, and honoraria for speaking or participation at meetings from CSL Behring, BBraun, and Biotest. Dietmar Fries has received study funding, as well as honoraria for consultancy and board activity from Astra Zeneca, AOP orphan, Baxter, Baer, BBraun, Biotest, CSL Behring, Delta Select, Dae Behring, Edwards, Fresenius, Glaxo, Haemoscope, Hemogem, Lilly, LFB, Mitsubishi Pharma, NovoNordisk, Octapharm, Pfizer, and Tem-Innovation outside the submitted work. The other authors (Tobias Hell, Johannes Bösch, Barbara Friesenecker, Benjamin Treichl, Ingo Lorenz, Daniel Stengg, Stefan Hruby, Bernd Wallner, Elgar Oswald, Mathias Ströhle, Christian Niederwanger, and Christian Irsara) declared no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
- Published
- 2020
- Full Text
- View/download PDF
243. Influence of factor XII deficiency on activated partial thromboplastin time (aPTT) in critically ill patients.
- Author
-
Bachler M, Niederwanger C, Hell T, Höfer J, Gerstmeyr D, Schenk B, Treml B, and Fries D
- Subjects
- Aged, Anticoagulants therapeutic use, Critical Illness, Female, Humans, Male, Middle Aged, Premedication, ROC Curve, Retrospective Studies, Venous Thromboembolism prevention & control, Factor XII Deficiency blood, Partial Thromboplastin Time
- Abstract
FXII deficiency results in spontaneous prolongation of activated partial thromboplastin time (aPTT), which is widely used to monitor thromboprophylaxis. Misinterpretation of spontaneously prolonged aPTT may result in omission of thromboembolic treatment or even unnecessary transfusion of blood products. This retrospective analysis was performed to calculate a threshold level of FXII resulting in aPTT prolongation. 79 critically ill patients with spontaneous prolongation of aPTT were included. A correlation analysis and a ROC curve for aPTT prolongation predicted by FXII level were created to find the FXII threshold level. Prolongation of aPTT was associated with disease severity. A significant inverse proportionality between FXII and aPTT was seen. A ROC curve for aPTT prolongation, predicted by FXII level (AUC 0.85; CI 0.76-0.93), revealed a FXII threshold level of 42.5%. Of our patients 50.6% experienced a FXII deficiency, in 80.0% of whom we found aPTT to be prolonged without a significantly higher bleeding rate. The FXII deficiency was more common in patients with higher SAPS3 scores, septic shock, transfusion of red blood cells and platelet concentrates as well as in patients receiving renal replacement therapy. Patients with a FXII deficiency and prolonged aPTT less often received anticoagulatory therapy although they were more severely ill. The rate of thromboembolic events was higher in these patients although the difference was not statistically significant. Of all patients with spontaneous aPTT prolongation 50.6% had a FXII level of 42.5% or less. Those patients received insufficient thromboembolic prophylaxis.
- Published
- 2019
- Full Text
- View/download PDF
244. [Edoxaban for stroke prevention in atrial fibrillation and treatment of venous thromboembolism: an expert position paper].
- Author
-
Weiss TW, Rohla M, Dieplinger B, Domanovits H, Fries D, Vosko MR, Gary T, and Ay C
- Subjects
- Administration, Oral, Anticoagulants, Humans, Atrial Fibrillation prevention & control, Factor Xa Inhibitors therapeutic use, Pyridines therapeutic use, Stroke, Thiazoles therapeutic use, Venous Thromboembolism prevention & control
- Abstract
Edoxaban is the most recent available representative of the Non-Vitamin K antagonist oral anticoagulants (NOAC). The approval was based on the largest phase III trials of NOACs for stroke prevention in patients with non-valvular atrial fibrillation (AF, ENGAGE-AF), and for the treatment of venous thromboembolism (VTE, HOKUSAI-VTE). In both trials, edoxaban was associated with similar efficacy and a significant reduction in bleeding events with respect to the pre-defined primary safety endpoints, as compared to warfarin.Additionally, the once daily dosing of edoxaban, the clinically investigated strategy for dose-reduction based on clearly defined criteria and the favorable pharmacokinetic profile might further support the clinical applicability of the substance.In the light of recent data, this expert consensus document aims to summarize the latest clinical trial results while providing a concise overview of current guideline recommendations on the management of patients with non-valvular AF and VTE.
- Published
- 2018
- Full Text
- View/download PDF
245. Transfusion Approaches and Mortality in Trauma Patients: A Narrative Review.
- Author
-
Fries D, Innerhofer P, and Spahn DR
- Subjects
- Hemorrhage mortality, Hemorrhage physiopathology, Hemostasis physiology, Humans, Survival Rate, Wounds and Injuries mortality, Wounds and Injuries physiopathology, Blood Transfusion methods, Hemorrhage therapy, Wounds and Injuries therapy
- Abstract
Competing Interests: Disclosure The authors report no conflicts of interest in this work.
- Published
- 2017
- Full Text
- View/download PDF
246. Reversal of trauma-induced coagulopathy using first-line coagulation factor concentrates or fresh frozen plasma (RETIC): a single-centre, parallel-group, open-label, randomised trial.
- Author
-
Innerhofer P, Fries D, Mittermayr M, Innerhofer N, von Langen D, Hell T, Gruber G, Schmid S, Friesenecker B, Lorenz IH, Ströhle M, Rastner V, Trübsbach S, Raab H, Treml B, Wally D, Treichl B, Mayr A, Kranewitter C, and Oswald E
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Treatment Outcome, Young Adult, Blood Coagulation Factors therapeutic use, Hemorrhage drug therapy, Hemorrhage etiology, Plasma, Wounds and Injuries complications
- Abstract
Background: Effective treatment of trauma-induced coagulopathy is important; however, the optimal therapy is still not known. We aimed to compare the efficacy of first-line therapy using fresh frozen plasma (FFP) or coagulation factor concentrates (CFC) for the reversal of trauma-induced coagulopathy, the arising transfusion requirements, and consequently the development of multiple organ failure., Methods: This single-centre, parallel-group, open-label, randomised trial was done at the Level 1 Trauma Center in Innsbruck Medical University Hospital (Innsbruck, Austria). Patients with trauma aged 18-80 years, with an Injury Severity Score (ISS) greater than 15, bleeding signs, and plasmatic coagulopathy identified by abnormal fibrin polymerisation or prolonged coagulation time using rotational thromboelastometry (ROTEM) were eligible. Patients with injuries that were judged incompatible with survival, cardiopulmonary resuscitation on the scene, isolated brain injury, burn injury, avalanche injury, or prehospital coagulation therapy other than tranexamic acid were excluded. We used a computer-generated randomisation list, stratification for brain injury and ISS, and closed opaque envelopes to randomly allocate patients to treatment with FFP (15 mL/kg of bodyweight) or CFC (primarily fibrinogen concentrate [50 mg/kg of bodyweight]). Bleeding management began immediately after randomisation and continued until 24 h after admission to the intensive care unit. The primary clinical endpoint was multiple organ failure in the modified intention-to-treat population (excluding patients who discontinued treatment). Reversal of coagulopathy and need for massive transfusions were important secondary efficacy endpoints that were the reason for deciding the continuation or termination of the trial. This trial is registered with ClinicalTrials.gov, number NCT01545635., Findings: Between March 3, 2012, and Feb 20, 2016, 100 out of 292 screened patients were included and randomly allocated to FFP (n=48) and CFC (n=52). Six patients (four in the FFP group and two in the CFC group) discontinued treatment because of overlooked exclusion criteria or a major protocol deviation with loss of follow-up. 44 patients in the FFP group and 50 patients in the CFC group were included in the final interim analysis. The study was terminated early for futility and safety reasons because of the high proportion of patients in the FFP group who required rescue therapy compared with those in the CFC group (23 [52%] in the FFP group vs two [4%] in the CFC group; odds ratio [OR] 25·34 [95% CI 5·47-240·03], p<0·0001) and increased needed for massive transfusion (13 [30%] in the FFP group vs six [12%] in the CFC group; OR 3·04 [0·95-10·87], p=0·042) in the FFP group. Multiple organ failure occurred in 29 (66%) patients in the FFP group and in 25 (50%) patients in the CFC group (OR 1·92 [95% CI 0·78-4·86], p=0·15)., Interpretation: Our results underline the importance of early and effective fibrinogen supplementation for severe clotting failure in multiple trauma. The available sample size in our study appears sufficient to make some conclusions that first-line CFC is superior to FFP., Funding: None., (Copyright © 2017 Elsevier Ltd. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
247. FITC-linked Fibrin-Binding Peptide and real-time live confocal microscopy as a novel tool to visualize fibrin(ogen) in coagulation.
- Author
-
Weiss N, Schenk B, Bachler M, Solomon C, Fries D, and Hermann M
- Abstract
Background and Aim : Although fibrinogen has been established as a key player in the process of coagulation, many questions about the role of fibrinogen under specific conditions remain. Confocal microscopic assessment of clot formation, and in particular the role that fibrinogen plays in this process, is commonly investigated using pre-labeled fibrinogen. This has a number of drawbacks, primarily that it is impossible to stain fibrin networks after their formation. The aim of the present study is to present an alternative for conveniently post-staining fibrin in a wide range of models/situations, in real time and with high resolution. Methods : We combined a peptide known to bind fibrin and linked it to fluorescein isothiocyanate (FITC), creating the FITC-Fibrin-Binding Peptide (FFBP). We subsequently tested its fibrin-binding capability in vitro under static conditions, as well as under simulated flow, using real-time live confocal microscopy. Results : Fibrin stained with FFBP overlaps with fibrin stained with fibrinogen pre-labeled with Alexa Fluor 647 following coagulation induction. In contrast to pre-labeled fibrinogen, FFBP also stains already formed fibrin networks. By combining FFBP with real-time live confocal microscopy even the visualization of single fibrin fibers is possible. Conclusions : These data indicate that FFBP is a valid and valuable tool for real-time live confocal assessment of clot formation. Relevance for patients: Our findings present a valuable alternative for the visualization of fibrin even after its formation, and we believe this approach will be particularly valuable for future investigations of important, but previously overlooked, aspects of clot formation., Competing Interests: C. Solomon was an employee of CSL Behring at the time of writing and previously received speaker honoraria and re-search support from Tem International and CSL Behring and travel support from Haemoscope Ltd (former manufacturer of TEG®). D. Fries has received honoraria for consulting, lecture fees and sponsoring for academic studies from the following companies: Astra Zeneca, AOP Orphan, Baxter, Bayer, B. Braun, Biotest, CSL Behring, Delta Select, Dade Behring, Edwards, Fresenius, Glaxo, Haemoscope, Hemogem, Lilly, LFB, Mitsubishi Pharma, NovoNordisk, Octapharm, Pfizer, Tem-Innovation. M. Hermann, N. Weiss, B. Schenk and M. Bachler have no conflicts of interest to disclose.
- Published
- 2017
248. Tranexamic acid for treatment and prophylaxis of bleeding and hyperfibrinolysis.
- Author
-
Pabinger I, Fries D, Schöchl H, Streif W, and Toller W
- Subjects
- Antifibrinolytic Agents administration & dosage, Dose-Response Relationship, Drug, Humans, Treatment Outcome, Blood Coagulation drug effects, Blood Coagulation Disorders drug therapy, Fibrinolysis drug effects, Hematology standards, Hemorrhage prevention & control, Practice Guidelines as Topic, Tranexamic Acid administration & dosage
- Abstract
Uncontrolled massive bleeding with subsequent derangement of the coagulation system is a major challenge in the management of both surgical and seriously injured patients. Under physiological conditions activators and inhibitors of coagulation regulate the sensitive balance between clot formation and fibrinolysis. In some cases, excessive and diffuse bleeding is caused by systemic activation of fibrinolysis, i. e. hyperfibrinolysis (HF). Uncontrolled HF is associated with a high mortality. Polytrauma patients and those undergoing surgical procedures involving organs rich in plasminogen proactivators (e. g. liver, kidney, pancreas, uterus and prostate gland) are at a high risk for HF. Antifibrinolytics, such as tranexamic acid (TXA) are used for prophylaxis and treatment of bleeding caused by a local or generalized HF as well as other hemorrhagic conditions. TXA is a synthetic lysine analogue that has been available in Austria since 1966. TXA is of utmost importance in the prevention and treatment of traumatic and perioperative bleeding due to the resulting reduction in perioperative blood loss and blood transfusion requirements. The following article presents the different fields of application of TXA with particular respect to indications and dosages, based on a literature search and on current guidelines.
- Published
- 2017
- Full Text
- View/download PDF
249. Therapeutic Plasma Transfusion in Bleeding Patients: A Systematic Review.
- Author
-
Levy JH, Grottke O, Fries D, and Kozek-Langenecker S
- Subjects
- Clinical Trials as Topic methods, Hemorrhage diagnosis, Humans, Plasma Substitutes administration & dosage, Platelet Transfusion methods, Blood Component Transfusion methods, Hemorrhage therapy, Plasma
- Abstract
Plasma products, including fresh frozen plasma, are administered extensively in a variety of settings from massive transfusion to vitamin K antagonist reversal. Despite the widespread use of plasma as a hemostatic agent in bleeding patients, its effect in comparison with other available choices of hemostatic therapies is unclear. We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, PubMed Central, and databases of ongoing trials for randomized controlled trials that assessed the efficacy and/or safety of therapeutic plasma as an intervention to treat bleeding patients compared with other interventions or placebo. Of 1243 unique publications retrieved in our initial search, no randomized controlled trials were identified. Four nonrandomized studies described the effect of therapeutic plasma in bleeding patients; however, data gathered from these studies did not allow for comparison with other therapeutic interventions primarily as a result of the low number of patients and the use of different (or lack of) comparators. We identified two ongoing trials investigating the efficacy and safety of therapeutic plasma, respectively; however, no data have been released as yet. Although plasma is used extensively in the treatment of bleeding patients, evidence from randomized controlled trials comparing its effect with those of other therapeutic interventions is currently lacking.
- Published
- 2017
- Full Text
- View/download PDF
250. Colloidophobia.
- Author
-
Ripollés Melchor J, Fries D, and Chappell D
- Published
- 2016
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.